Advancing best-in-
class and first-in-class candidates


HER2, including oncogenic mutations
IAM-H1 is a highly potent and irreversible tyrosine kinase inhibitor (TKI) that selectively targets HER2 and HER2 mutants, while sparing EGFR. Amplification and mutations of HER2 drive a wide range of human cancers. HER2 TKIs have had limited success due to a compensatory mechanism that increases the required therapeutic index beyond that of available pan-ERBB and HER2 inhibitors.
IAM-H1 exhibits over 1000-fold selectivity against EGFR, favorable PK and safety profiles, preferential tumor enrichment, and effective CNS penetrance. Together these make IAM-H1 a breakthrough molecule for realizing the full therapeutic potential of inhibiting HER2 signaling, while avoiding EGFR-driven toxicity. In vivo, IAM-H1 has demonstrated favorable efficacy and tolerability across a range of HER2 tumor models, including intracranial models, outperforming benchmark TKIs and antibody-drug conjugates (ADCs).
A multi-center Phase I trial is scheduled to commence patient dosing in early 2024.
CDK2/4
IAM-C1 is a first-in-class small molecule inhibitor designed to specifically target CDK2 and CDK4, two cell-cycle kinases that are frequently dysregulated in various cancers. Through its selective inhibition of CDK2/4 while preserving other closely related CDKs including CDK1, CDK6, and CDK9, IAM-C1 has the potential to provide expanded therapeutic benefits compared to clinically approved CDK4/6 inhibitors.
IAM-C1 represents a promising new approach to address cell-cycle dysregulation in cancer, building upon the learnings from two decades of research and clinical experience. CDK4/6 inhibitors are the standard of care for patients with HR+/HER2- metastatic breast cancer (mBC) in both first- and subsequent-line settings. Despite the success of these agents, many patients demonstrate either intrinsic or acquired resistance to the approved CDK4/6 inhibitors. HR+/HER2- mBC remains a significant cause of morbidity and mortality, presenting extraordinary unmet patient need.
The more targeted approach of IAM-C1 offers a more favorable safety profile by reducing dose-limiting toxicities associated with non-CDK2/4 kinases, including CDK6.
Protein-complex target for solid tumors
Effector protein for solid tumors
Delivering development candidates years faster than industry norms

News & Media
Read our recent announcements
.jpg)
Iambic Therapeutics Announces Close of Oversubscribed $100 Million Series B Financing to Advance AI-Discovered Therapeutics into Clinical Development and Enters Collaboration with NVIDIA
.jpg)